IMMUNOVANT, INC.
IMVTLoading price...
Overview
Previous Close26.29
Open30.30
Ask33.17
Bid18.67
Day's Range30.10 - 36.28
52 Week Range13.79 - 36.28
PE Ratio(TTM)--
Market Cap7.3B
Volume19.56M
Avg. Volume1.4M
12 Months Earnings-464.20M
12 Months Revenue0.00
Performance
ABSCAGR
| YTD | 1 Month | 3 Months | 1 Year | 2 Years | 5 Years | 10 Years | |
|---|---|---|---|---|---|---|---|
| No results to display | |||||||
Profit/Loss
| PARTICULARS | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 487.17M | 438.15M | 270.21M | 208.28M | 156.03M |
| Profit after Tax (Net Income) | -464.20M | -413.84M | -259.34M | -210.96M | -156.73M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Durham, United States
Website: https://immunovant.com
Executive Chairperson of the Board: Dr. Frank M. Torti M.B.A., M.D.
Employees: 362
About Company:
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.